2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14771
    Imeglimin 775351-65-0 98%
    Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.
    Imeglimin
  • HY-14902
    Tofogliflozin 903565-83-3 98%
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.
    Tofogliflozin
  • HY-15327
    1alpha, 25-Dihydroxy VD2-d6 216244-04-1 99%
    1alpha, 25-Dihydroxy VD2-d66 is a deuterated form of vitamin D.
    1alpha, 25-Dihydroxy VD2-d6
  • HY-15384
    Picoprazole 78090-11-6 98%
    Picoprazole is a specific inhibitor of H+/K+-ATPase with IC50 of 3.1±0.4 μM.
    Picoprazole
  • HY-16266
    JNJ-DGAT1-A 1092067-85-0 98%
    JNJ-DGAT1-A is a selective DGAT1 inhibitor. JNJ-DGAT1-A inhibits DGAT1 activity and TG synthesis.
    JNJ-DGAT1-A
  • HY-16708
    ZLN024 723249-01-2 98%
    ZLN024 is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
    ZLN024
  • HY-18057
    BVT-3498 376641-49-5 98%
    BVT-3498 (AMG-311) is an inhibitor for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
    BVT-3498
  • HY-19030
    TA-1801 88352-44-7 98%
    TA-1801 is a hypolipidemic agent.
    TA-1801
  • HY-19083
    SIM-6080 118790-68-4 98%
    SIM-6080 is a calcium antagonist and inhibits the proliferation of rat aortic myocytes and reduces aortic atherosclerosis in rabbits.
    SIM-6080
  • HY-19164
    BOF-4272 142181-44-0 98%
    BOF-4272 is a xanthine oxidase/xanthine dehydrogenase inhibitor. BOF-4272 can be used for hyperuricemia research.
    BOF-4272
  • HY-19218
    RPR-106541 159001-35-1 98%
    RPR-106541 is a 17-thiosteroid. RPR 106541 has potent glucocorticosteroid activity. RPR 106541 also has demonstrable effects on carbohydrate and lipid metabolism.
    RPR-106541
  • HY-19394
    CLX-0921 249886-47-3 98%
    CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes.
    CLX-0921
  • HY-19425
    NS-220 377731-45-8 98%
    NS-220 is an orally active PPARα agonist with high subtype selectivity, with EC50 values of 1.9×10-8 M, 9.6×10-6 M and >10-4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes.
    NS-220
  • HY-19690
    Ritobegron hydrochloride 476333-91-2 98%
    Ritobegron, a prodrug of the active compound, KUC-7322, is a selective β3 -adrenoceptor agonist. Ritobegron decreases intravesical pressure with minimal effects on the cardiovascular system.
    Ritobegron hydrochloride
  • HY-19859
    AMG-222 tosylate 1163719-08-1 98%
    AMG-222 (tosylate) is a DPP-IV inhibitor that can be used in the research of type II diabete.
    AMG-222 tosylate
  • HY-24063
    Malonyl-L-Carnitine chloride 2417978-94-8 98%
    Malonyl-L-Carnitine (chloride) is an ester product.
    Malonyl-L-Carnitine chloride
  • HY-28247
    N-Formylkynurenine 1022-31-7 98%
    N-Formylkynurenine is an intermediate in the catabolism of tryptophan. It is a formylated derivative of kynurenine. The formation of N-formylkynurenine is catalyzed by heme dioxygenases.
    N-Formylkynurenine
  • HY-32338
    Tacalcitol monohydrate 93129-94-3 99.85%
    Tacalcitol monohydrate (1,24(R)-Dihydroxyvitamin D3; 1.
    Tacalcitol monohydrate
  • HY-34781
    4'-Trifluoromethyl-2-biphenyl carboxylic acid 84392-17-6 ≥98.0%
    4'-Trifluoromethyl-2-biphenyl carboxylic acid is an orally active hypolipidemic agent.
    4'-Trifluoromethyl-2-biphenyl carboxylic acid
  • HY-48289
    PKA/AKAP-IN-2 304888-67-3 98%
    PKA/AKAP-IN-2 (15109) is a non-peptide inhibitor of the interaction between protein kinase A (PKA) and A kinase anchoring proteins (AKAP). PKA/AKAP-IN-2 can be utilized in research related to cAMP disturbance associated diseases.
    PKA/AKAP-IN-2
Cat. No. Product Name / Synonyms Application Reactivity